Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hygieia Inc. maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently faces 1 pending office action. This workload is distributed across 1 distinct examiner and 1 distinct art unit, showing a singular point of contact within the patent office for its current filings.
The busiest examiner identified in the portfolio is LIN, JERRY. This individual is currently handling 1 pending office action for the company. Because the total count of pending office actions is 1, this examiner manages the complete set of active prosecution challenges for Hygieia Inc. at this time.
The concentration of the portfolio into 1 distinct art unit suggests a specific technological focus within the broader Biotechnology & Pharmaceuticals sector. Practitioners should note that the current prosecution activity is limited to this single pending matter under the review of LIN, JERRY, allowing for a highly specialized approach to resolving the outstanding office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIN, JERRY | 1 | 72.3% | +14.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18213501 | Systems, Devices, and Methods for Alleviating Glucotoxicity and Restoring Pancreatic Beta-Cell Function in Advanced Diabetes Mellitus | LIN, JERRY | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18213501 | Systems, Devices, and Methods for Alleviating Glucotoxicity and Restoring Pancreatic Beta-Cell Function in Advanced Diabetes Mellitus | LIN, JERRY | 1671 | §103§112DP | Non-Final OA | — | Pending | Jun 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial